Indolent B-Cell Non-Hodgkin Lymphoma — Trials

Indolent B-Cell Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

617 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 172
Recruiting: 85
Ph III recruiting: 4
Growth YoY: +34.6%
Industry share: 22%
Top sponsor: City of Hope Medical Center
Termination share: 34.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (109)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07420959	ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia	not yet recruiting	Phase 1 / Phase 2	38	Mayo ClinicOTHER	1	Jul 8, 2026	clinicaltrials
NCT07169565	Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia	not yet recruiting	Phase 1	21	Institute of Hematology & Blood Diseases Hospital, ChinaOTHER	0	Sep 11, 2025	clinicaltrials